Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common eye drop speed up wound healing after skin cancer surgery?

NCT ID NCT07384767

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study tests whether a topical timolol solution, normally used as eye drops, can help skin wounds heal faster when left open after surgery. 220 adults who choose to let their surgical wounds heal naturally will apply either timolol or a placebo gel daily for 12 weeks. Researchers will compare wound closure and infection rates between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
timolol 0.5% ophthalmic solution
What this could lead to
If it works, this could offer a simple, low-cost way to help skin wounds heal faster after surgery without needing stitches.
What could go wrong
This is an early phase 2 trial, so results are not yet proven. The benefit may be small or no different from standard care, and daily application for 12 weeks may be inconvenient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female subject of any race 18 years old or older 2. Patient opt to heal by secondary intention healing after discussion of reconstructive options following excision 3. Patients undergoing Mohs micrographic surgery, standard surgical excision, or electrodesiccation and curettage (ED\&C) whose wounds are managed by secondary intention healing. 4. Willing to send photos of ulcer at 3 week intervals with ruler measuring length by width 5. Able to give informed consent themselves Exclusion Criteria: 1. Cyst excisions (due to concern for inflammation) 2. Site shows evidence of infection (defined as a moderate or severe rating of all of the following clinical signs/symptoms: 1) increased warmth, 2) increased pain, 3) erythema, and 4) malodorous exudate at Screening or at Randomization (Visit 1), OR total organism count \> 1 x 105 colony forming units (CFU) from the screening visit study ulcer culture sample) 3. Severe COPD/asthma/cardiac arrhythmia 4. Hx of documented beta blocker allergy 5. Cognitive impairment 6. Has medically documented history of Human Immunodeficiency Virus (HIV) 7. Has active malignancy on the study limb 8. Has immunodeficiency as defined by serum IgG, IgA, and IgM less than one-half the lower limit of normal 9. Has severe protein malnutrition as defined by serum albumin \< 2.5 g/dL 10. Has serum aspartate aminotransferase (AST, SGOT, GOT) or serum alanine aminotransferase (ALT, SGPT, GPT) levels greater than twice the upper limit of normal 11. Has fatigue, palpitations, dyspnea, and/or angina at rest 12. Has a medically documented or self-reported history, within the previous 12 months from date of Screening Visit, of alcohol or drug abuse, particularly methadone or heroin 13. Has received previous treatment with the following during the 60 days prior to Screening: Immunosuppressive agents, radiation, chemotherapy, growth factors (epidermal growth factor, tumor necrosis factor, transforming growth factor, platelet derived growth factor, etc.) 14. Has received previous treatment with the following during the 30 days prior to screening: the site of the study ulcer, split- or full-thickness skin graft at the site of the study ulcer, biologically-active (or engineered) cellular or acellular product(s) at the site of the study ulcer, investigational drug or device 15. Has history of bradycardia (heart rate less than 60) 16. Has ESR\>70mm/hr and CRP\>100 mg/L at time of screening 17. Has medically documented history of hypotension/orthostatic hypotension and/or symptomatic hypotension (systolic blood pressure below 90 and diastolic blood pressure less than 60). (Note: There is no standard testing regimen protocol for orthostatic hypotension, even for patients starting on oral timolol) 18. Currently taking asthma or COPD medications (as documented in chart) 19. Has a medically documented diagnosis of myasthenia gravis, untreated hyperthyroidism, , Type 2, Type 3 heart block, cardiogenic shock, overt cardiac failure 20. Female who is pregnant or refuses to use adequate contraceptive methods and is of childbearing age during the trial 21. Prisoners, institutionalized individuals or vulnerable population

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Excision margin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Margins of Excision

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UC Davis Health- Dermatology

    Sacramento, California, 95816, United States

  • VA Medical Center- Sacramento

    Sacramento, California, 95655, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.